IKT 주가 차트
IKT 재무
Inhibikase Therapeutics Inc
$2.35
0.85%
$0.02
종가: Jul 27, 16:00:00 GMT-4
$2.29
-2.55%
$-0.06
애프터마켓: Jul 27, 19:51:54 GMT-4
뒤로
Inhibikase Therapeutics Inc (IKT) 재무
주요 통계
이전 종가
$2.33
시가
$2.36
일일 범위
$2.29 - $2.39
52주 범위
$1.33 - $2.29
거래량
507.3K
평균 거래량
1.0M
배당수익률
--
EPS(TTM)
-1.15
시가총액
$302.3M
IKT란 무엇인가요?
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
